Jacob S, Streeper R S, Fogt D L, Hokama J Y, Tritschler H J, Dietze G J, Henriksen E J
Department of Physiology, University of Arizona College of Medicine, Tucson, USA.
Diabetes. 1996 Aug;45(8):1024-9. doi: 10.2337/diab.45.8.1024.
Insulin resistance of muscle glucose metabolism is a hallmark of NIDDM. The obese Zucker (fa/fa) rat--an animal model of muscle insulin resistance--was used to test whether acute (100 mg/kg body wt for 1 h) and chronic (5-100 mg/kg for 10 days) parenteral treatments with a racemic mixture of the antioxidant alpha-lipoic acid (ALA) could improve glucose metabolism in insulin-resistant skeletal muscle. Glucose transport activity (assessed by net 2-deoxyglucose [2-DG] uptake), net glycogen synthesis, and glucose oxidation were determined in the isolated epitrochlearis muscles in the absence or presence of insulin (13.3 nmol/l). Severe insulin resistance of 2-DG uptake, glycogen synthesis, and glucose oxidation was observed in muscle from the vehicle-treated obese rats compared with muscle from vehicle-treated lean (Fa/-) rats. Acute and chronic treatments (30 mg.kg-1.day-1, a maximally effective dose) with ALA significantly (P < 0.05) improved insulin-mediated 2-DG uptake in epitrochlearis muscles from the obese rats by 62 and 64%, respectively. Chronic ALA treatment increased both insulin-stimulated glucose oxidation (33%) and glycogen synthesis (38%) and was associated with a significantly greater (21%) in vivo muscle glycogen concentration. These adaptive responses after chronic ALA administration were also associated with significantly lower (15-17%) plasma levels of insulin and free fatty acids. No significant effects on glucose transporter (GLUT4) protein level or on the activities of hexokinase and citrate synthase were observed. Collectively, these findings indicate that parenteral administration of the antioxidant ALA significantly enhances the capacity of the insulin-stimulatable glucose transport system and of both oxidative and nonoxidative pathways of glucose metabolism in insulin-resistant rat skeletal muscle.
肌肉葡萄糖代谢的胰岛素抵抗是2型糖尿病的一个标志。肥胖的Zucker(fa/fa)大鼠——一种肌肉胰岛素抵抗的动物模型——被用来测试抗氧化剂α-硫辛酸(ALA)的外消旋混合物进行急性(100mg/kg体重,持续1小时)和慢性(5 - 100mg/kg,持续10天)肠胃外治疗是否能改善胰岛素抵抗的骨骼肌中的葡萄糖代谢。在有无胰岛素(13.3nmol/l)存在的情况下,测定分离的肱三头肌中的葡萄糖转运活性(通过净2-脱氧葡萄糖[2-DG]摄取评估)、净糖原合成和葡萄糖氧化。与接受溶媒治疗的瘦(Fa/-)大鼠的肌肉相比,接受溶媒治疗的肥胖大鼠的肌肉中观察到2-DG摄取、糖原合成和葡萄糖氧化存在严重的胰岛素抵抗。ALA进行急性和慢性治疗(30mg·kg-1·天-1,最大有效剂量)分别使肥胖大鼠肱三头肌中胰岛素介导的2-DG摄取显著(P<0.05)提高了62%和64%。慢性ALA治疗增加了胰岛素刺激的葡萄糖氧化(33%)和糖原合成(38%),并与体内肌肉糖原浓度显著更高(21%)相关。慢性ALA给药后的这些适应性反应还与血浆胰岛素和游离脂肪酸水平显著降低(15 - 17%)相关。未观察到对葡萄糖转运蛋白(GLUT4)蛋白水平或己糖激酶和柠檬酸合酶活性有显著影响。总的来说,这些发现表明抗氧化剂ALA的肠胃外给药显著增强了胰岛素抵抗大鼠骨骼肌中胰岛素刺激的葡萄糖转运系统以及葡萄糖代谢的氧化和非氧化途径的能力。